A real life experience with novel biosimilar InfimabTM in biologic naive patients with active rheumatoid arthritis
Abstract
Objective: To determine the efficacy and safety of novel infliximab biosimilar, InfimabTM (IFB) in rheumatoid arthritis (RA) patients.
Materials and Methods: Eight patients with active RA who failed to demonstrate clinical improvement with methotrexate were enrolled. Post consent, patients were administered infliximab biosimilar 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks on demand. Patients were assessed for Health assessment questionnaire (HAQ, India Score), disease activity score 28 (DAS 28), Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC), erythrocyte sedimentation rate (ESR) and Visual Analogue Scale (VAS) score at baseline and at each visit. They were also observed for any adverse effects or tuberculosis infection. Wilcoxon sign rank test was used to assess the change between baseline to each follow-up visit.
Results: On any average 3 infusions were administered to patients. At visit 3 there was significant improvement in HAQ score (p=0.046), WOMAC score (p=0.018), Tender joints count (p=0.027), swollen joints count (p=0.027) and also in general health (p=0.043). Though the VAS scores and ESR values decreased at visit 3, they were not significant. At the end of visit 5, there was considerable decrease in the tested parameters, except in tender joint count. None of the patients reported any adverse effects, indicating that infliximab biosimilar was well-tolerated in tested patients.
Conclusion: In this preliminary trial conducted in eight RA patients, treatment with IFB improved clinical outcomes and was well-tolerated in RA patients who failed initial treatment with methotrexate
Downloads
References
2. Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis.2017;76(1):58-64.doi:10.1136/ annrheumdis -2015-207764.
3. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biol. 2009;3:183─191.
4. Gupta B, Ritu G, Ashok K, Madhu B. Rheumatoid Arthritis Research in India:A Scientometric Assessment of Publications during 2007-2016. Ortho Res Online J. 3 (1). OPROJ. 000552.2018. doi: 10.31031 / OPROJ. 2018. 03.000552
5. Jacobs I, Petersel D, Isakov L, Lula S, Lea Sewell K. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence. Bio Drugs. 2016;30(6):525-70. doi: https://doi.org/ 10. 1007/s40259-016-0201-6
6. Schulze-Koops H, Skapenko A. Biosimilars in rheu-matology: A review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017; 56(4):iv30-iv48. doi: 10.1093/rheumatology/ kex277.
7. Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017;23(11):1932-1943. doi: 10.3748/wjg.v23.i11.1932.
8. GaBI Online - Generics and Biosimilars Initiative. Positive phase III data for Epirus infliximab biosimilar [www.gabionline.net ]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Oct 3]. Available from: www.gabionline.net/Biosimilars/ Research / Positive-phase-III-data-for- Epirus-infliximab - biosimilar. Accessed on July 01, 2019.
9. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, et al. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016;54(4):315-22. doi: 10.5414/CP202530.
10. Kay J, Wyand M, Chandrashekara S, Olakkengil DJ, Bhojan K, Bhatia G, et al. BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study. Abstract number L20. 2014 ACR/ ARHP Annual Meeting.
11. Amin SN, Kapadia A, Shamil M. Short-term and long-term outcomes of biosimilar infliximab (BOW015) treatment in rheumatoid arthritis–A single-centre retrospective study. ABS312. Int J Rheumat Dis.2017; 20(1):17─131.
12. BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study. Available from: https://clinicaltrials. Gov/ct2/show/NCT02683564. Accessed on July 01, 2019.
13. Ezard C, Kumari R, Willott R, Butt S, Gadsby K, Deighton C. What is meant by active disease in the NICE recommendation on use of combination therapy in early RA. Rheumatology (Oxford). 2012;51(5):947-8.doi:10.1093/rheumatology/ker513. Epub 2012 Jan 31.
14. Sharma P, Mukherjee S, Sarkar RN, Mandal SK, Naorem S. OPC0120: Real world experience with Infliximab Biosimilar (BOW015®) in Ankylosing spondylitis – A sub-group analysis of the East India cohort. Poster Presentations. Indian J Rheumatol. 2018; 13(Suppl S2):93-241.
15. Vijay KR Rao, Arindam Nandy Roy, Shamil M. Long-Term Sustainability of Response with Infliximab Biosimilar (BOW015) in Ankylosing Spondylitis – Efficacy and Safety Analysis from Two Centers in South India. IRACON. 2017. Lucknow.
16. Agrawal I, Roy A, Kiran R, Rao V, Sarkar R, Naorem S, et al. AB0690 Clinical experience with infliximab biosimilar (BOW015) in ankylosing spondylitis- efficacy and safety analysis from an Indian perspective. Annals Rheumat Dis. 2017;76:1295.
17. Kay J, Chopra A, Chandrashekara S, Olakkengil DJ, Bhojan KS, Bhatia G, et al. OP0012 A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. Annal Rheumat Dis. 2014;73(Suppl 2):64. doi: 10.1136/annrheumdis-2014-eular.1595
18. Kay J, Chopra A, Lassen C, Shneyer L, Wyand M. FRI0117 BOW015, A Biosimilar Infliximab: Disease Activity and Disability Outcomes from a Phase 3 Active Comparator Study in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. Ann Rheumat Dis. 2015;74(Suppl 2):462-463.
19. Taylor P, Wyand M, Knight A, Costantino C, Lassen C. FRI0163 Efficacy of The Biosimilar BOW 015, Compared To Originator Infliximab, Initiated at Moderate and Severe Disease Activity Thresholds in Rheumatoid Arthritis. Ann Rheumat Dis. 2016;75 (Suppl 2):488-489. doi: 10.1136/annrheumdis-2016-eular.4143.
OAI - Open Archives Initiative
Therapoid
